Registrieren

Registierung erfolgt in Kürze...
Fleebs-Logo
Details werden geladen...

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in ...

Company Announcement

Ähnliche Seiten

https://www.manilatimes.net/2026/06/14/tmt-newswire/globenewswire/genmab-announces-epcoritamab-monotherapy-and-epcoritamab-based-combination-regimens-demonstrate-high-response-rates-in-elderly-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl/2364956

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | ...

https://www.manilatimes.net/2026/06/14/tmt-newswire/globenewswire/genmab-announces-epcoritamab-monotherapy-and-epcoritamab-based-combination-regimens-demonstrate-high-response-rates-in-elderly-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl/2364956
https://www.finanznachrichten.de/nachrichten-2026-05/68556378-infex-therapeutics-announces-positive-phase-iia-results-for-resp-x-in-non-cystic-fibrosis-bronchiectasis-patients-colonised-with-pseudomonas-aeruginos-399.htm

Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa

https://www.finanznachrichten.de/nachrichten-2026-05/68556378-infex-therapeutics-announces-positive-phase-iia-results-for-resp-x-in-non-cystic-fibrosis-bronchiectasis-patients-colonised-with-pseudomonas-aeruginos-399.htm
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/candel-therapeutics-announces-publication-in-the-lancet-oncology-of-pivotal-phase-3-data-demonstrating-significant-improvement-in-disease-free-survival-with-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer/2356805

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loc...

https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/candel-therapeutics-announces-publication-in-the-lancet-oncology-of-pivotal-phase-3-data-demonstrating-significant-improvement-in-disease-free-survival-with-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer/2356805
https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/60-degrees-pharmaceuticals-announces-positive-recommendation-from-data-safety-monitoring-board-for-b-free-phase-2-study-of-tafenoquine-for-treatment-of-chronic-babesiosis-patients-with-severe-fatigue/2376683

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue...

https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/60-degrees-pharmaceuticals-announces-positive-recommendation-from-data-safety-monitoring-board-for-b-free-phase-2-study-of-tafenoquine-for-treatment-of-chronic-babesiosis-patients-with-severe-fatigue/2376683
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/orion-pharma-announces-first-results-from-phase-12-teades-trial-with-tead-inhibitor-odm-212-in-patients-with-advanced-solid-tumours/2355072

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours | The Manila Times

https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/orion-pharma-announces-first-results-from-phase-12-teades-trial-with-tead-inhibitor-odm-212-in-patients-with-advanced-solid-tumours/2355072
https://www.manilatimes.net/2026/06/22/tmt-newswire/globenewswire/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-transplantation/2369969

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transp...

https://www.manilatimes.net/2026/06/22/tmt-newswire/globenewswire/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-transplantation/2369969